Nurix Therapeutics, Inc. (NRIX) stock
NRIXNasdaqPharmaceutical PreparationsFiscal year ends November 30
Financials through Q3 FY2026, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 13, 2026Score 15/3073% below fair value
$15.48−0.12 (-0.77%)
Close on Nov 13, 2026Market cap $1.69BP/E 6.7Yield 0.00%
Nurix Therapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Nurix Therapeutics's profit margin for the twelve months ending Aug 31, 2026 was 42.0%. For fiscal 2025 it was -314.9%, against -354.9% the year before. The highest annual figure on record is -69.7% in fiscal 2019.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | -314.9% | +39.9 |
| FY2024 | Nov 30, 2024 | -354.9% | −167.9 |
| FY2023 | Nov 30, 2023 | -187.0% | +280.0 |
| FY2022 | Nov 30, 2022 | -466.9% | −73.0 |
| FY2021 | Nov 30, 2021 | -393.9% | −151.3 |
| FY2020 | Nov 30, 2020 | -242.7% | −172.9 |
| FY2019 | Nov 30, 2019 | -69.7% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026CQ3 2026 | Aug 31, 2026 | 81.7% | +1176.5 |
| Q2 FY2026CQ2 2026 | May 31, 2026 | -990.1% | −891.4 |
| Q1 FY2026CQ1 2026 | Feb 28, 2026 | -1394.3% | −1089.0 |
| Q4 FY2025CQ4 2025 | Nov 30, 2025 | -576.1% | −135.4 |
| Q3 FY2025CQ3 2025 | Aug 31, 2025 | -1094.8% | −705.9 |
| Q2 FY2025CQ2 2025 | May 31, 2025 | -98.7% | +269.7 |
| Q1 FY2025CQ1 2025 | Feb 28, 2025 | -305.4% | −55.0 |
| Q4 FY2024CQ4 2024 | Nov 30, 2024 | -440.7% | −164.0 |
| Q3 FY2024CQ3 2024 | Aug 31, 2024 | -388.9% | −188.7 |
| Q2 FY2024CQ2 2024 | May 31, 2024 | -368.4% | −289.3 |
| Q1 FY2024CQ1 2024 | Feb 29, 2024 | -250.3% | +70.8 |
| Q4 FY2023CQ4 2023 | Nov 30, 2023 | -276.8% | +412.0 |
| Q3 FY2023CQ3 2023 | Aug 31, 2023 | -200.3% | +223.3 |
| Q2 FY2023CQ2 2023 | May 31, 2023 | -79.1% | +318.0 |
| Q1 FY2023CQ1 2023 | Feb 28, 2023 | -321.1% | +121.0 |
| Q4 FY2022CQ4 2022 | Nov 30, 2022 | -688.7% | −179.0 |
| Q3 FY2022CQ3 2022 | Aug 31, 2022 | -423.6% | −142.3 |
| Q2 FY2022CQ2 2022 | May 31, 2022 | -397.1% | −25.1 |
| Q1 FY2022CQ1 2022 | Feb 28, 2022 | -442.1% | +42.3 |
| Q4 FY2021CQ4 2021 | Nov 30, 2021 | -509.8% | −212.0 |
| Q3 FY2021CQ3 2021 | Aug 31, 2021 | -281.3% | +172.0 |
| Q2 FY2021CQ2 2021 | May 31, 2021 | -372.0% | −553.3 |
| Q1 FY2021CQ1 2021 | Feb 28, 2021 | -484.4% | −51.8 |
| Q4 FY2020CQ4 2020 | Nov 30, 2020 | -297.7% | +428.3 |
| Q3 FY2020CQ3 2020 | Aug 31, 2020 | -453.3% | −430.4 |
| Q2 FY2020CQ2 2020 | May 31, 2020 | 181.3% | +213.8 |
| Q1 FY2020CQ1 2020 | Feb 29, 2020 | -432.6% | −403.6 |
| Q4 FY2019CQ4 2019 | Nov 30, 2019 | -726.0% | – |
| Q3 FY2019CQ3 2019 | Aug 31, 2019 | -22.9% | – |
| Q2 FY2019CQ2 2019 | May 31, 2019 | -32.5% | – |
| Q1 FY2019CQ1 2019 | Feb 28, 2019 | -29.1% | – |
See a number that looks wrong?